PT  - JOURNAL ARTICLE
AU  - Luis Alberto García Rodríguez
AU  - Lucía Cea Soriano
AU  - Stine Munk Hald
AU  - Jesper Hallas
AU  - Yanina Balabanova
AU  - Gunnar Brobert
AU  - Pareen Vora
AU  - Mike Sharma
AU  - David Gaist
TI  - Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
AID  - 10.1136/heartjnl-2020-317887
DP  - 2020 Dec 11
TA  - Heart
PG  - heartjnl-2020-317887
4099  - http://heart.bmj.com/content/early/2020/12/10/heartjnl-2020-317887.short
4100  - http://heart.bmj.com/content/early/2020/12/10/heartjnl-2020-317887.full
AB  - Objective To evaluate associations between oral anticoagulant (OAC) discontinuation and risk of ischaemic stroke (IS) among patients with atrial fibrillation (AF).Methods We undertook a population-based cohort study with nested case–control analysis using UK primary care electronic health records (IQVIA Medical Research Data-UK) and linked registries from the Region of Southern Denmark (RSD). Patients with AF (76 882 UK, 41 526 RSD) were followed to identify incident IS cases during 2016–2018. Incident IS cases were matched by age and sex to controls. Adjusted ORs for OAC discontinuation (vs current OAC use) were calculated using logistic regression.Results We identified 616 incident IS cases in the UK and 643 in the RSD. ORs for IS with any OAC discontinuation were 2.99 (95% CI 2.31 to 3.86, UK) and 2.30 (95% CI 1.79 to 2.95, RSD), for vitamin K antagonist discontinuation they were 2.38 (95% CI 1.72 to 3.30, UK) and 1.83 (95% CI 1.34 to 2.49, RSD), and for non-vitamin K antagonist oral anticoagulant discontinuation they were 4.59 (95% CI 2.97 to 7.08, UK) and 3.37 (95% CI 2.35 to 4.85, RSD). ORs were unaffected by time since discontinuation and duration of use. Annually, up to 987 IS cases in the UK and 132 in Denmark could be preventable if OAC therapy is not discontinued.Conclusions Our results suggest that patients with AF who discontinue OAC therapy have a significant twofold to threefold higher risk of IS compared with those who continue therapy. Addressing OAC discontinuation could potentially result in a significant reduction in AF-attributed IS.